Overview

A Phase 1/2 Crossover Study to Assess EXP039 for Myopia or Hyperopia

Status:
Enrolling by invitation
Trial end date:
2021-08-30
Target enrollment:
Participant gender:
Summary
Assess the Safety, Pharmacodynamics, and Efficacy of EXP039 Ophthalmic Solution in Participants with Myopia or Hyperopia
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Canyon City Eyecare
Collaborator:
Nevakar, Inc.
Treatments:
Pilocarpine